Strategic alliance with OsteoTronix for advanced MR imaging solutions

m2m Imaging Corp., the leading developer of next-generation high-definition preclinical and clinical Magnetic Resonance Imaging (MRI) coils and solutions announced it has entered in to a strategic alliance with OsteoTronix Ltd. (Swansea, UK). 

OsteoTronix has developed a unique new medical imaging diagnostic technique based on MRI data, Structural Spectroscopy™, which provides structural scale and frequency information about anatomy relevant to a variety of disease states including cancer and osteoporosis.  Initial studies have demonstrated that Structural Spectroscopy can detect small changes in bone and vessels in-vivo, creating the potential for a wide range of novel clinical diagnostic techniques and research tools which can be implemented on any existing clinical or preclinical MRI system. 

Matching m2m's high performance conventional and cryogenic MRI coils with software solutions from OsteoTronix enables acquisition of dramatically improved image data, resulting in better and faster results.

m2m's existing customers will have access to the Osteotronix Structural Spectroscopytm products through m2m, and OsteoTronix customers will have access to m2m's coils and accessories through OsteoTronix.

About m2m Imaging Corp.
m2m Imaging, with offices in USA and Australia produce's high-definition imaging and work flow solutions for life science applications in the MRI, PET, CT and SPECT analytical, preclinical and clinical research environments. m2m's MRI coil and accessory portfolio consists of products that have provided solutions to enable otherwise unobtainable results for research applications all over the world.

On the Web: www.m2mimaging.com